Q4 2024 Earnings Call Transcript March 12, 2025 Assertio Holdings, Inc. misses on earnings expectations. Reported EPS is ...

Brendan O'Grady; Chief Executive Officer; Assertio Holdings Inc. Ajay Patel; Chief Financial Officer, Senior Vice ...

Assertio Holdings Inc (ASRT) reports strong Rovedon sales and strategic leadership additions, while navigating legal and competitive pressures.

Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 MillionFull Year Net Product Sales $120.8Million, Rolvedon ...

Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8 Million, Rolvedon Sales Exceed $60.0 Million Full Year Cash Flow from ...

Indocin net product sales in the fourth quarter were $5.5 million, compared to $5.7 million in the prior quarter, reflecting pricing changes following a generic entrant late in 2023. To access the ...

Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing ...

Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing ...

Long-term use of NSAIDs has been linked to a reduced risk of developing dementia due to their anti-inflammatory properties. A large study highlights the importance of sustained use, rather than ...